gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

Prognostic value of amino-acid PET with FET in 85 patients with newly diagnosed glioma-suspicious intracerebral lesions

Prognostischer Wert des Aminosäure-PET mit FET bei 85 Patienten mit neu diagnostizierten, gliomverdächtigen intrazerebralen Läsionen

Meeting Abstract

  • corresponding author F. Floeth - Department of Neurosurgery, Heinrich-Heine-University, Düsseldorf
  • G. Reifenberger - Department of Neuropathology, Heinrich-Heine-University, Düsseldorf
  • K. J. Langen - Brain Imaging Center West, Institute of Medicine, Research Center Jülich, Jülich
  • D. Pauleit - Institute of Nuclear Chemistry, Research Center Jülich, Jülich
  • H. J. Steiger - Department of Neurosurgery, Heinrich-Heine-University, Düsseldorf
  • M. Sabel - Department of Neurosurgery, Heinrich-Heine-University, Düsseldorf

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. Doc10.05.-09.01

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2005/05dgnc0126.shtml

Veröffentlicht: 4. Mai 2005

© 2005 Floeth et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective

The aim of this prospective study was to determine the prognostic value of metabolic imaging with PET using O-(2-[18F] fluoroethyl)-L-tyrosine (FET) in patients presenting with glioma-suspicious lesions.

Methods

85 consecutive patients with newly diagnosed and untreated glioma suspicious lesions underwent evaluation with contrast-enhanced MRI and FET-PET. In 72 patients, histological diagnosis was obtained by serial biopsy procedures wheareas 13 patients were followed up without histological diagnosis. The initial FET-uptake of each lesion before treatment was correlated to the clinical course and outcome. Clinical follow-up of the patients ranged from 12 months to 7.5 years, with a mean follow-up time of 37 months.

Results

Gliomas were histologically diagnosed in 63 patients. In 9 patients, histology revealed diagnostically unspecific changes including edema, reactive gliosis and microglia activation. All 11 glioblastomas were invariably FET-PET positive, with 10 (91%) patients showing progressive disease and 9 (82%) succumbing to their tumour during follow-up. Among the 22 anaplastic gliomas, 20 were PET positive. Twelve of the patients (60%) showed progressive disease and 10 (50%) died. Two anaplastic gliomas were PET negative and did not progress so far. Twenty-one of the 30 gliomas of WHO grade II were FET positive. Eleven of these patients (52%) showed progressive disease and 5 (24%) died. In contrast, 9 WHO grade II gliomas were FET negative. Among these cases, 8 (89 %) remained stable whereas one patient showed progressive disease. Three of the 9 histologically unspecific lesions were FET positive, all 3 (100%) progressed to glioblastoma. and 2 died (66%). The remaining 6 FET negative and histologically unspecific lesions all remained clinically stable. Two of the 13 lesions without histological diagnosis were FET positive and one progressed to glioblastoma. The other 11 FET-PET negative lesions showed no clinical progression.

Conclusions

Our data indicate that the FET-uptake is a strong prognostic indicator in intracerebral gliomas. More than 95% of the patients with FET-PET negative lesions (27 of 28) demonstrated a benign course without clinical or radiological progression. In contrast, more than 65% of the patients with FET-PET positive lesions (37 of 57) showed progressive disease and 46% of these patients died.